Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vorapaxar Sulfate

FDA-approved product (tablet, oral), marketed as Zontivity.

Registered studies
15
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vorapaxar Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Myocardial infarction
  • Peripheral arterial disease
  • Recurrent thrombophlebitis
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Platelet aggregation inhibitors excl. heparin
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

15registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vorapaxar Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vorapaxar Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Vorapaxar and Lower Extremity Bypass Grafts

    NCT02975583 · start 2017-10-01

    Registered record
    Registry ID
    NCT02975583
    Conditions
    Peripheral Artery Disease
    Interventions
    Vorapaxar; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-10-01
    Completion
    2018-01-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Artery Disease
    InterventionVorapaxar; Placebos
    PhasePhase 4
    Registry statusWithdrawn

  • Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

    NCT02660866 · start 2016-07

    Registered record
    Registry ID
    NCT02660866
    Conditions
    Peripheral Arterial Disease
    Interventions
    Placebo + background APT + SMT; Vorapaxar 2.08 mg/d + background APT + SMT.
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2016-07
    Completion
    2019-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeripheral Arterial Disease
    InterventionPlacebo + background APT + SMT; Vorapaxar 2.08 mg/d + background APT + SMT.
    PhasePhase 4
    Registry statusUnknown

  • Vorapaxar in the Human Endotoxemia Model

    NCT02875028 · start 2016-06

    Registered record
    Registry ID
    NCT02875028
    Conditions
    Healthy Volunteers
    Interventions
    Vorapaxar; Placebo; LPS
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-06
    Completion
    2016-11-30
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionVorapaxar; Placebo; LPS
    PhasePhase 4
    Registry statusCompleted

  • Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

    NCT02548650 · start 2016-03-25

    Registered record
    Registry ID
    NCT02548650
    Conditions
    Myocardial Infarction; Diabetes Mellitus; Peripheral Arterial Disease
    Interventions
    Vorapaxar; Clopidogrel; Aspirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-03-25
    Completion
    2019-02-14
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction; Diabetes Mellitus; Peripheral Arterial Disease
    InterventionVorapaxar; Clopidogrel; Aspirin
    PhasePhase 4
    Registry statusCompleted

  • Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

    NCT02545933 · start 2016-02

    Registered record
    Registry ID
    NCT02545933
    Conditions
    Myocardial Infarction
    Interventions
    Prasugrel; Vorapaxar; Aspirin; Ticagrelor
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02
    Completion
    2020-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyocardial Infarction
    InterventionPrasugrel; Vorapaxar; Aspirin; Ticagrelor
    PhasePhase 4
    Registry statusCompleted

  • Vorapaxar on Thrombin Generation and Coagulability

    NCT03207451 · start 2016-01-01

    Registered record
    Registry ID
    NCT03207451
    Conditions
    Coronary Artery Disease; Peripheral Vascular Disease; Myocardial Infarction
    Interventions
    Vorapaxar; Vorapaxar and Aspirin; Vorapaxar and Clopidogrel; Vorapaxar, Aspirin, and Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-01-01
    Completion
    2018-08-01
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease; Peripheral Vascular Disease; Myocardial Infarction
    InterventionVorapaxar; Vorapaxar and Aspirin; Vorapaxar and Clopidogrel; Vorapaxar, Aspirin, and Clopidogrel
    PhasePhase 4
    Registry statusCompleted

  • Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

    NCT02394730 · start 2015-09

    Registered record
    Registry ID
    NCT02394730
    Conditions
    HIV
    Interventions
    vorapaxar; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-09
    Completion
    2018-01
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventionvorapaxar; Placebo
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access

    NCT02475837 · start 2015-08-26

    Registered record
    Registry ID
    NCT02475837
    Conditions
    AV Fistula
    Interventions
    Vorapaxar sulfate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-08-26
    Completion
    2017-10-23
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAV Fistula
    InterventionVorapaxar sulfate; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Bioequivalence Study of SCH 530348 2.5 mg Tablets (P06558)

    NCT01358344 · start 2010-08

    Registered record
    Registry ID
    NCT01358344
    Conditions
    Acute Coronary Syndrome
    Interventions
    Pantoprazole; SCH 530348 (high percentage); SCH 530348 (standard percentage)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-12
    Enrolment
    173

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome
    InterventionPantoprazole; SCH 530348 (high percentage); SCH 530348 (standard percentage)
    PhasePhase 1
    Registry statusCompleted

  • Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)

    NCT00617123 · start 2008-07-01

    Registered record
    Registry ID
    NCT00617123
    Conditions
    Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident
    Interventions
    Vorapaxar 2.5 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07-01
    Completion
    2010-10-01
    Enrolment
    258

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident
    InterventionVorapaxar 2.5 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

    NCT00527943 · start 2007-12-01

    Registered record
    Registry ID
    NCT00527943
    Conditions
    Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
    Interventions
    Vorapaxar; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2007-12-01
    Completion
    2011-07-01
    Enrolment
    12,944

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Myocardial Ischemia; Myocardial Infarction
    InterventionVorapaxar; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

    NCT00526474 · start 2007-09-01

    Registered record
    Registry ID
    NCT00526474
    Conditions
    Atherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident; Peripheral Arterial Disease
    Interventions
    Vorapaxar; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-09-01
    Completion
    2011-12-01
    Enrolment
    26,449

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Ischemia; Myocardial Infarction; Cerebrovascular Accident +1 more
    InterventionVorapaxar; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016)

    NCT00684203 · start 2006-12-01

    Registered record
    Registry ID
    NCT00684203
    Conditions
    Atherosclerosis; Myocardial Ischemia; Myocardial Infarction
    Interventions
    Vorapaxar; Placebo; Aspirin; Clopidogrel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-12-01
    Completion
    2007-10-01
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Myocardial Ischemia; Myocardial Infarction
    InterventionVorapaxar; Placebo; Aspirin; Clopidogrel
    PhasePhase 2
    Registry statusCompleted

  • Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

    NCT00684515 · start 2006-09-21

    Registered record
    Registry ID
    NCT00684515
    Conditions
    Cerebral Infarction
    Interventions
    Vorapaxar 2.5 mg; Vorapaxar 1 mg; Placebo; Aspirin 75-150 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-09-21
    Completion
    2007-11-08
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCerebral Infarction
    InterventionVorapaxar 2.5 mg; Vorapaxar 1 mg; Placebo; Aspirin 75-150 mg
    PhasePhase 2
    Registry statusCompleted

  • Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

    NCT00132912 · start 2005-08-30

    Registered record
    Registry ID
    NCT00132912
    Conditions
    Arterial Obstructive Diseases; Coronary Disease
    Interventions
    SCH 530348
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08-30
    Completion
    2007-01-28
    Enrolment
    1,030

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Obstructive Diseases; Coronary Disease
    InterventionSCH 530348
    PhasePhase 2
    Registry statusCompleted